Interestingly, ALDH1A1 and ALDH2 expression are weakly correlated (Figure 6A), and unlike ALDH1A1, ALDH2 expression is not associated with recurrent tumors (Figure 1 vs. Supporting Figure S1), LSC+ cells (Figure 2 vs. Supporting Figure S2), or M6/M7 FAB subtypes (Supporting Figures S3 and S4), suggesting that ALDH2 has a distinct relationship with risk in AML. This evidence concerns the gene FANCB and acute myeloid leukemia.